With a predicted revenue of US$ 47,430 million in 2023 and a projected compound annual growth rate of 5.4%, the global kinase inhibitors in autoimmune diseases industry size is expected to develop significantly. The remarkable US$ 80,252 million market by 2033 is predicted to be driven by considerable technology improvements in the healthcare industry, which …